Evidence map›Paper›PMID 41697516›Full record

Trial reportAdvances in therapy2026

Impact of Diffusing Lung Capacity for Carbon Monoxide on Mortality Risk in Patients with ASMD: Insights from a Post Hoc Analysis.

Wim A Wuyts, Francesco Bonella, Maurizio Scarpa, Venediktos Kapetanakis, Pragya Shukla, Marie Fournier, Maja Gasparic, Ruth Pulikottil-Jacob

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wim A WuytsUnit for Interstitial Lung Diseases, Department of Pulmonology, UZ Leuven, Belgium. wim.wuyts@uzleuven.be.
Francesco BonellaCenter for Interstitial and Rare Lung Disease at Ruhrlandklinik, University of Essen, Essen, Germany.
Maurizio ScarpaRegional Coordinating Centre for Rare Diseases, MetabERN, Udine University Hospital, Udine, Italy.
Venediktos KapetanakisEvidera, London, UK.
Pragya ShuklaEvidera, St-Laurent, QC, Canada.
Marie FournierSanofi, Gentilly, France.
Maja GasparicSanofi, Amsterdam, The Netherlands.
Ruth Pulikottil-JacobSanofi, Reading, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAcid sphingomyelinase deficiency (ASMD) is a rare lysosomal storage disorder with heterogenous clinical manifestations, including interstitial lung disease (ILD). Respiratory manifestations are the leading causes of mortality in patients with ASMD type B and type A/B. In ILD, the percent predicted diffusing capacity of the lungs for carbon monoxide (DL

methodsThis post hoc analysis explored the relationship between DL

resultsA total of 68 patients (prospective study, n = 40; retrospective study, n = 28) diagnosed with ASMD type B or type A/B during childhood (aged 1-12 years) with ≥ 1 DL

conclusionsTo our knowledge, this is the first analysis to explore the relationship between DL

Indexed as

Carbon MonoxideLung Diseases, InterstitialPulmonary Diffusing CapacityAdolescentAdultChildChild, PreschoolFemaleHumansInfantMaleMiddle AgedProportional Hazards ModelsProspective StudiesRetrospective StudiesCarbon MonoxideAcid sphingomyelinase deficiencyDiffusing capacity of the lungs for carbon monoxideInterstitial lung diseaseMortalityOverall survivalPost hoc analysis

Identifiers

PMID41697516
PMCPMC13065610

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.